Nature Biotechnology 24, 277 (2006)
doi:10.1038/nbt0306-277a
Convergence in biomedical technologyAscher Shmulewitz2, Robert Langer1
& John Patton31 Robert Langer is Institute Professor at the Massachusetts Institute of Technology in Cambridge, Massachusetts 02139, USA. rlanger@mit.edu 2 Ascher Shmulewitz is at Medgenesis Partners Ltd in Tel-Aviv, Israel. ascher@Incumed.com 3 John S. Patton is at Nektar Therapeutics and former head of drug delivery at Genentech. jruddock@ca.nektar.com An entrepreneur and a pioneer in innovative technologies trade views with an industry veteran on the likely importance of convergent technology in health care.Technology convergence is already a reality in communications, where it has generated new industry sectors. Increasing emphasis on translational research in biomedicine, together with the cross-fertilization of such fields as biotech, nanotech and information technology, now promise similar interdisciplinary, convergent solutions for disease prevention, screening, diagnosis, therapy, monitoring and management. Here, the views of an entrepreneur and a leading researcher on the potential of convergent biomedical technologies are contrasted with the historical perspective of an industry veteran.
The ascendance of combination products
A historical perspective on convergence technologye
|
